IRCT20200408046990N9招募中3 期
Evaluation of protective effect of nano-silymarin oral formulation on vancomycin-induced nephrotoxicity
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •Age between 18 to 60
- •Take vancomycin at a dose of 15-20 mg / kg two to three times a day for at least one week
- •Signing a written consent by the patient
- •Creatinine clearance greater than 90 ml/min based on Cockcroft-Gault formula
排除标准
- •Underlying renal impairment such as glomerulonephritis, polycystic kidney disease, renal stone, interstitial nephritis, renal artery stenosis and renal carcinoma
- •Receive nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, tacrolimus and furosemide, etc. simultaneously
- •History of allergy to products containing silymarin
- •History of acute kidney injury
- •Pregnancy and lactation
- •Consumption of vitamin and herbal antioxidant supplements such as vitamins C and E or curcumin and ...
研究者
相似试验
招募中
3 期
Evaluation of the efficacy of Silymarin in patients with COVID-19IRCT20201024049130N1Artesh University of Medical Sciences50
已完成
2 期
silymarin and cisplatin induced nephrotoxicityCondition 1: oesophagus cancer. Condition 2: Stomach Cancer.Malignant neoplasm of oesophagusMalignant neoplasm of stomachIRCT201207013043N6tehran university of medical science,58
尚未招募
3 期
Effect of silymarin in the treatment of patients with depressioIRCT20160804029191N4Mashhad University of Medical Sciences80
尚未招募
2 期
Silymarin capsule in COVID-19COVID-19 disease.COVID-19U07.1IRCT20180103038199N10Mashhad University of Medical Sciences140
招募中
3 期
Evaluating the effectiveness of Silymarin on the prevention of gentamicin nephrotoxicityGentamicin-induced renal toxicity in hospitalized patients.Other bacterial diseasesA30-A49IRCT20161010030246N3Shiraz University of Medical Sciences60